DMRT1-mediated reprogramming drives development of cancer resembling human germ cell tumors with features of totipotency
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
In vivo reprogramming provokes a wide range of cell fate conversion. Here, we discover that in vivo induction of higher levels of OSKM in mouse somatic cells leads to increased expression of primordial germ cell (PGC)-related genes and provokes genome-wide erasure of genomic imprinting, which takes place exclusively in PGCs. Moreover, the in vivo OSKM reprogramming results in development of cancer that resembles human germ cell tumors. Like a subgroup of germ cell tumors, propagated tumor cells can differentiate into trophoblasts. Moreover, these tumor cells give rise to induced pluripotent stem cells (iPSCs) with expanded differentiation potential into trophoblasts. Remarkably, the tumor-derived iPSCs are able to contribute to non-neoplastic somatic cells in adult mice. Mechanistically, DMRT1, which is expressed in PGCs, drives the reprogramming and propagation of the tumor cells in vivo. Furthermore, the DMRT1-related epigenetic landscape is associated with trophoblast competence of the reprogrammed cells and provides a therapeutic target for germ cell tumors. These results reveal an unappreciated route for somatic cell reprogramming and underscore the impact of reprogramming in development of germ cell tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 Trophoblastic differentiation of D-OSKM tumor cells. a Representative histological images of D-OSKM pancreatic tumors containing trophoblast giant cell (TGC) clusters. Dotted lines indicate TGC clusters (>3 cells/high-power field [×400]). Scale bars: 1000 μm (left), 200 μm (right). b Incidence of tumors containing trophoblast giant cells in S-/D-OSKM chimeric mice. c Quantification of TGC cluster area in S-/D-OSKM kidney tumors (normal kidney, n = 5; S-OSKM kidney tumor, n = 16; D-OSKM kidney tumor following Dox treatment at various doses [2.0 mg/mL, n = 17; 0.4 mg/mL, n = 4; 0.25 mg/mL, n = 7; 0.13 mg/mL, n = 4]). Data are presented as means ± SD of biologically independent samples (Kruskal–Wallis test and Dunn’s multiple-comparison test, two-sided). d Representative histological images and immunostaining for CDX2 and PL-1 of D-OSKM pancreatic tumors (upper panels). Dotted lines indicate TGC clusters. Scale bars: 200 μm. Immunofluorescence staining for OCT4 and CDX2 of D-OSKM kidney tumors (lower panels). Scale bars: 50 μm. e (Left) qRT-PCR analyses of trophoblast-related gene expression in S-/D-OSKM kidney tumors. Data are presented as means ± SD of biological triplicates. Relative expression levels to TSCs are shown (one-way ANOVA and Dunnett’s multiple-comparison test, two-sided) (Right) Heatmap showing relative expression of trophoblast-related genes in S-/D-OSKM kidney tumors. Color range is shown using a log2 scale. f Lineage-tracing system for Nanog-expressing cells. Mice were treated with tamoxifen (2.0 mg) six times every other day during Dox treatment. g Immunostaining for Venus in kidney tumors (n = 4). Arrows indicate TGCs. Dotted lines indicate the TGC cluster. Scale bars: 200 μm. h Schematic illustration of an experimental protocol for in vivo D-OSKM reprogramming of somatic cells deficient for Cdx2 or Tead4. i, Representative macroscopic and histological images of Cdx2 KO and Tead4 KO D-OSKM pancreatic tumors. Scale bars: 1000 μm (middle), 500 μm (right). j Quantification of TGC cluster area in control (n = 10), Cdx2 KO (n = 4), and Tead4 KO (n = 4) D-OSKM pancreatic tumors. Data are presented as means ± SD of biologically independent samples (Kruskal–Wallis test and Dunn’s multiple-comparison test, two-sided).](https://figures.cochat.ai/paper-figures/6303a5a3ac3f4b0cba391ef5b809bfd4/dmrt1-mediated-reprogramming-drives-development-of-cancer-resembling-human-germ-figure-3.jpg)



![Fig. 7 DMRT1-mediated reprogramming provides a therapeutic target for human germ cell tumors. a Heatmap showing transcriptional correlation between human PSCs, germ-line cells, and 23 types of human cancer; analysis was performed using KeyGenes77 (AGC, male advanced germ cell; SSC, spermatogonial stem cell). RNA-seq data of ESCs, PGCs, and AGCs were obtained from GSE6339278, and those of SSCs and spermatogonia were obtained from GSE9228079. RNA-seq data from 23 types of human cancer were obtained from the Cancer Genome Atlas (TCGA) (ACC: adrenocortical carcinoma [n = 79]; BLCA: bladder urothelial carcinoma [n = 408]; BRCA: breast-invasive carcinoma [n = 1092]; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma [n = 304]; CHOL: cholangiocarcinoma [n = 36]; COAD: colon adenocarcinoma [n = 456]; ESCA: esophageal carcinoma [n = 164]; GBM: glioblastoma multiforme [n = 166]; HNSC, head and neck squamous cell carcinoma [n = 501]; KIRC: kidney renal clear-cell carcinoma [n = 530]; KIRP: kidney renal papillary cell carcinoma [n = 289]; LGG: brain lower-grade glioma [n = 512]; LIHC: liver hepatocellular carcinoma [n = 371]; LUAD: lung adenocarcinoma [n = 515]; LUSC: lung squamous cell carcinoma [n = 501]; MESO: mesothelioma [n = 86]; PCPG: pheochromocytoma and paraganglioma [n = 179]; PRAD: prostate adenocarcinoma [n = 496]; SKCM: skin cutaneous melanoma [n = 468]; STAD: stomach adenocarcinoma [n = 380]; TGCT/non-seminoma: testicular germ cell tumor/nonseminoma [n = 68]; TGCT/seminoma: testicular germ cell tumor/seminoma [n = 66]; THCA: thyroid carcinoma [n = 502]; UCEC: uterine corpus endometrial carcinoma [n = 555]). b Heatmap indicates robust Z-scores of proportions of open-chromatin regions specific to 23 types of cancer with consensus motifs for each of the indicated transcription factors (see details in “Methods” section). Transcription factors whose binding motifs are present in the highest proportions of TGCT cancer-specific open-chromatin regions are shown. Each cancer-type-specific peak set, determined by ATAC-seq, was obtained from TCGA in the NIH Genomic Data Commons portal80 (ACC, n = 9; BLCA, n = 10; BRCA, n = 74; CESC, n = 2; CHOL, n = 5; COAD, n = 38; ESCA, n = 18; GBM, n = 9; HNSC, n = 9; KIRC, n = 16; KIRP, n = 34; LGG, n = 13; LIHC, n = 17; LUAD, n = 22; LUSC, n = 16; MESO, n = 7; PCPG, n = 9; PRAD, n = 26; SKCM, n = 13; STAD, n = 21; TGCT, n = 9; THCA, n = 14; UCEC, n = 13). PanCancer represents 562,709 reproducible ATAC-seq peaks obtained from 410 tumor samples80. c Cell proliferation assay of Dmrt1-induced human GCT cell lines. Data are presented as the means ± SD of three independent experiments. d Representative images of Dmrt1-induced NCCIT at Day 5. A magnified image of a multinuclear syncytiotrophoblast-like cell is shown in the lower panel. Scale bars: 100 μm. e qRT-PCR analyses for expression of trophoblast-related genes in Dmrt1-expressing NCCIT cells. mCherry-positive Dmrt1-expressing cells were isolated using FACS. Data are presented as the means ± SD of biological triplicates. The mean expression level of Dox OFF cells was set to 1 (t-test, two-sided).](https://figures.cochat.ai/paper-figures/b2f790fda2d34210be1f64c200e0d61a/dmrt1-mediated-reprogramming-drives-development-of-cancer-resembling-human-germ-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, such a desirable outcome is only obtained when OSKM transcription factors are expressed in a controlled and transient fashion; their prolonged and exaggerated activation results in oncogenesis.140”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [140]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Cited by
Meta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy
Chehelgerdi, M., Behdarvand Dehkordi, F., Chehelgerdi, M., Kabiri, H., Salehian-Dehkordi, H., Abdolvand, M., Salmanizadeh, S., Rashidi, M., Niazmand, A., Ahmadi, S., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01873-0 · Cited by 175
Epigenetic reprogramming as a key to reverse ageing and increase longevity
Pereira, B., Correia, F. P., Alves, I. A., Costa, M., Gameiro, M. D., Martins, A. P., & Saraiva, J. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102204 · Cited by 128
Cheng, H., Shang, D., & Zhou, R. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01197-3 · Cited by 79
Cellular plasticity in reprogramming, rejuvenation and tumorigenesis: a pioneer TF perspective
Huyghe, A., Trajkova, A., & Lavial, F. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.07.013 · Cited by 56
Metadata
- Authors
- Taguchi, J., Shibata, H., Kabata, M., Kato, M., Fukuda, K., Tanaka, A., Ohta, S., Ukai, T., Mitsunaga, K., Yamada, Y., Nagaoka, S. I., Yamazawa, S., Ohnishi, K., Woltjen, K., Ushiku, T., Ozawa, M., Saitou, M., Shinkai, Y., Yamamoto, T., & Yamada, Y.
- Affiliations
- Institute of Medical Science, The University of Tokyo (JP)
- Kyoto University (JP)
- RIKEN (JP)
- The University of Tokyo (JP)
- Corresponding author
- Yamada, Yosuke
- Yamada, Yasuhiro
- ORCID
- Venue
- Nature Communications
- Published
- 2021-08-19
- Volume
- 12
- Issue
- 1
- Pages
- 5041-5041
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC8377058
- OpenAlex
- W3194092796
- Cited by
- 46
- References
- 81
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 19 · 2023: 12 · 2022: 4
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion)
- Funders
- Naito Foundation
- Takeda Science Foundation
- Japan Agency for Medical Research and Development (CREST, JP19gm1110004h9903, JP18cm0106203h0003, 17jm0210039h0005)
- Research Center Network for Realization of Regenerative Medicine
- Ministry of Education, Culture, Sports, Science and Technology (CREST)
- Princess Takamatsu Cancer Research Fund
- Japan Society for the Promotion of Science (20K15801, 18H03991, 18H05530, 20H03162, 17H06098, CREST, 19H03418, 19K21352, 20H05384, 18H04026)
- Core Research for Evolutional Science and Technology
- Strategic International Collaborative Research Program
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Syndromes and Imprinting
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Keywords
- DMRT1, OSKM, somatic cell reprogramming, germ cell tumors, primordial germ cells, induced pluripotent stem cells, trophoblast differentiation, totipotency, epigenetic reprogramming, tumor propagation, therapeutic target
- MeSH terms
- Animals, Cell Differentiation, Cells, Cultured, Female, Humans, Mice, Inbred ICR, Neoplasms, Neoplasms, Germ Cell and Embryonal, Transcription Factors, Genomic Imprinting, Animals, Genetically Modified, Epigenesis, Genetic, Cell Line, Tumor, Mice, Induced Pluripotent Stem Cells, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DMRT1-mediated reprogramming drives development of cancer resembling human germ cell tumors with features of totipotency. https://app.cochat.ai/papers/10.1038/s41467-021-25249-4
- The paper
- Taguchi, J., Shibata, H., Kabata, M., Kato, M., Fukuda, K., Tanaka, A., Ohta, S., Ukai, T., Mitsunaga, K., Yamada, Y., Nagaoka, S. I., Yamazawa, S., Ohnishi, K., Woltjen, K., Ushiku, T., Ozawa, M., Saitou, M., Shinkai, Y., Yamamoto, T., & Yamada, Y. (2021). DMRT1-mediated reprogramming drives development of cancer resembling human germ cell tumors with features of totipotency. Nature Communications. https://doi.org/10.1038/s41467-021-25249-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.